Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.

Neuropharmacology - 1 Jan 2022

Senkevich Konstantin, Rudakou Uladzislau, Gan-Or Ziv

Abstract excerpt

Parkinson's disease (PD) is defined as a complex disorder with multifactorial pathogenesis, yet a more accurate definition could be that PD is not a single entity, but rather a mixture of different diseases with similar phenotypes. Attempts to classify subtypes of PD have been made based on clinical phenotypes or biomarkers. However, the most practical approach, at least for a portion of the patients, could be to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Genes, Recessive
Share to Glucosylceramidase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Molecular Targeted Therapy

Share to Parkinson Disease

Share to Precision Medicine

Share to Ubiquitin-Protein Ligases

Source

Identifiers

PMID: 34626666
DOI: 10.1016/j.neuropharm.2021.108822

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.PMID 34626666Read ↗

Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.Semantic proximity Read ↗

The genetic background of Parkinson's disease and novel therapeutic targets.Semantic proximity Read ↗

GBA1-and LRRK2-directed Treatments: The Way Forward.Semantic proximity Read ↗

Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism.Semantic proximity Read ↗

Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.Semantic proximity Read ↗

GBA-associated PD: chances and obstacles for targeted treatment strategies.Semantic proximity Read ↗

Genetic Forms of Parkinson's Disease.Semantic proximity Read ↗

From disease to syndrome: the evolution of Parkinson's as a heterogeneous entity.Semantic proximity Read ↗

Disease‑Modifying Therapies for Parkinson’s Disease: Biological Mechanisms, Pharmacological Strategies, and Clinical PipelineSemantic proximity Read ↗

Leucine-Rich Repeat Kinase 2 in Parkinson’s Disease: Updated from Pathogenesis to Potential Therapeutic TargetSemantic proximity Read ↗

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.Semantic proximity Read ↗

Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.